Header

Multiple Myeloma Clinical Trials

Category:Adult
Status:Active

Displaying all 27 Trial

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide m...

Diagnosis: Multiple Myeloma, Lymphoma

Phase: 2

Protocol Number: 16-113

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-571

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide expo...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-199

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-313

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma

Diagnosis: Multiple Myeloma

Phase: 1 / 2

Protocol Number: 15-519

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 13-581

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-054

A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Durvalumab - ...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-237

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-522

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: - Trametinib - Dabrafenib

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-352

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstrom's Macroglobulinemia (WM).

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-235

A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients

This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or daratu...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-259

A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last ...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-224

A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)

This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 vs ibrutinib in subjects with MYD88 Mutation Waldenström's Macroglobulinemia.

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-338

Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Da...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-212

Study of bb21217 in Multiple Myeloma

Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-379

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-652

Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the ...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-595

A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

To evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients will be given a 3 day cour...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-551

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

This is a Phase Ib, open-label, multicenter, global study designed to assess the safety and tolerability of RO6870810 as monotherapy and in combination with daratumumab in participants with relapse...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-404

A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

This is an open-label, multi-center, international, Phase 1 study to assess the safety, PK/PD and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with RRMM. All eligi...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-653

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) admin...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-611

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.

Diagnosis: Waldenstrom's Macroglobulinemia, Multiple Myeloma

Phase:

Protocol Number: 17-164

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in p...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 18-151

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnos...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-610

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having ...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 18-604

'